HOME >> BIOLOGY >> NEWS
Celebrex may be safe for preterm labor, preliminary study finds

St. Louis, Sept. 23, 2002 -- The drug celecoxib may be a safer alternative for treating preterm labor than traditional therapies, according to a preliminary study led by Washington University School of Medicine in St. Louis. The study is published at the end of the month in the September issue of the American Journal of Obstetrics and Gynecology, and appears on the journal's website today.

One of the established treatments to prevent preterm delivery is indomethacin, a drug used to slow uterine contractions and delay delivery. But indomethacin is associated with severe side effects. Recent research suggests that celecoxib, also known as celebrex, may be a safer alternative. This study is the first clinical trial testing celecoxib in pregnant women.

"Celecoxib appears to be safer, particularly for the fetus," says Yoel Sadovsky, M.D., director of the Division of Genetics, Maternal-Fetal Medicine and Ultrasound at the School of Medicine. "These preliminary results also suggest that celecoxib is just as effective, and we are currently planning a larger trial to further examine its effectiveness."

The study was a combined effort between Washington University and Northwestern University. Sadovsky, also associate professor of obstetrics and gynecology and of cell biology and physiology, led the study. The first authors are Catherine S. Stika, M.D., at Northwestern University and Gilad A. Gross, M.D., assistant professor of obstetrics and gynecology at Washington University.

According to the American College of Obstetrics and Gynecology, about 1 in every 10 births in the United States occurs within the first 37 weeks of pregnancy and therefore is considered "preterm." Preterm labor is responsible for about 75 percent of newborn deaths not related to birth defects, and preterm infants often experience life-long complications.

Indomethacin, one of the standard drugs used to treat preterm labor, prevents the production of a type of p
'"/>

Contact: Gila Z. Reckess
reckessg@msnotes.wustl.edu
314-286-0109
Washington University School of Medicine
23-Sep-2002


Page: 1 2

Related biology news :

1. Case researchers substantiate bacterial link to preterm birth through mice studies
2. New ACOG guidelines on progesterone to prevent preterm birth praised by March of Dimes
3. Preeclampsia linked with higher risk of preterm delivery
4. Preeclampsia linked with higher risk of preterm delivery and later-life vascular disease
5. Predicting preterm birth still nearly impossible, study in New England Journal finds
6. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
7. Two-drug approach might shorten painful labor, reduce Caesarean sections
8. Society report encourages preliminary sex analysis of clinical trial data
9. Contract bridge enhances the immune system, according to a preliminary study by researchers at UC Berkeley
10. Novel anti-cancer agent shows minimal side effects with preliminary evidence of tumor shrinkage
11. Student science contest participation influences study, career choices, alumni say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... ... June 14, 2019 , ... Emtec, Inc.®, a global ... joint presentation with Versiti’s CIO at the Healthcare Industry User Group (HIUG) ... Resort. , Versiti Vice President and Chief Information Officer, Lynne Briggs, will present ...
(Date:6/11/2019)... AUCKLAND, New Zealand (PRWEB) , ... June 12, ... ... a wide range of antibody discovery services, Abveris plans to leverage the Geneious ... , Dr. Colby Souders, Chief Technology Officer at Abveris, says: “The Geneious ...
(Date:6/6/2019)... , ... June 05, 2019 , ... ... as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent ... preeminent anatomic pathology platform that provides services to more than one dozen hospitals ...
Breaking Biology News(10 mins):
(Date:5/14/2019)... TOWNSHIP, N.J. (PRWEB) , ... May 13, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... new Heliumleak.com company website. The redesigned website aims to improve LDA’s ability to ...
(Date:5/7/2019)... ... May 06, 2019 , ... "The new Liquid ... of repositories being asked to store cellular products being used in adoptive ... who are world leaders, who have shared their expertise in building and managing ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability to provide various ... Inc. aims to enhance customer satisfaction through the effective implementation of its ...
(Date:5/2/2019)... (PRWEB) , ... May 02, 2019 , ... ... genetics testing company, will present results documenting discrepancies between U.S. insurer policies for ... for patients at risk for hereditary breast and ovarian cancer (HBOC). ...
Breaking Biology Technology:
Cached News: